The prevalence and prognostic value of BRAF mutation in thyroid cancer.
OBJECTIVE
To examine the prevalence of BRAF mutation among thyroid cancer histologic subtypes and determine the association of BRAF mutation with indicators of poor prognosis for papillary thyroid cancer and patient outcome.


BACKGROUND
The appropriate extent of surgical treatment, adjuvant therapy and follow-up monitoring for thyroid cancer remains controversial. Advances in the molecular biology of thyroid cancer have helped to identify candidate markers of disease aggressiveness. A commonly found genetic alternation is a point mutation in the BRAF oncogene (BRAF V600E), which is primarily found in papillary thyroid cancer and is associated with more aggressive disease.


METHODS
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer). Univariate and multivariate analyses were performed to determine the association of BRAF V600E with clinicopathologic factors and patient outcome.


RESULTS
: The prevalence of BRAF V600E mutation was higher in conventional papillary thyroid cancer (51.0%) than in follicular variant of papillary thyroid cancer (24.1%) and follicular thyroid cancer (1.4%) (P < 0.0001). In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years. Multivariate analysis showed that BRAF V600E mutation [OR (95% CI) = 4.2 (1.2-14.6)] and lymph node metastasis [OR (95% CI) = 7.75 (2.1-28.5)] were independently associated with recurrent and persistent disease in patients with conventional papillary thyroid cancer.


CONCLUSIONS
BRAF V600E mutation is primarily present in conventional papillary thyroid cancer. It is associated with an aggressive tumor phenotype and higher risk of recurrent and persistent disease in patients with conventional papillary thyroid cancer. Testing for this mutation may be useful for selecting initial therapy and for follow-up monitoring.
Kebebew
Electron
E
Department of Surgery, University of California, San Francisco, San Francisco, California 94143-1674, USA. kebebewe@surgery.ucsf.edu
Weng
Julie
J
Bauer
Juergen
J
Ranvier
Gustavo
G
Clark
Orlo H
OH
Duh
Quan-Yang
QY
Shibru
Daniel
D
Bastian
Boris
B
Griffin
Ann
A
D002291:Carcinoma, Papillary / Q000235:genetics*; D018265:Carcinoma, Papillary, Follicular / Q000235:genetics; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D015995:Prevalence; D011379:Prognosis; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D018709:Statistics, Nonparametric; D013964:Thyroid Neoplasms / Q000235:genetics*
C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
World J Surg. 2000 Aug;24(8):942-51
10865038
Thyroid. 2003 Apr;13(4):381-7
12804106
Cancer Res. 2003 Aug 1;63(15):4561-7
12907632
J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7
12970315
J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404
14602780
J Clin Endocrinol Metab. 2004 May;89(5):2414-20
15126572
Cancer. 2004 Jul 1;101(1):3-27
15221985
Clin Endocrinol (Oxf). 2004 Aug;61(2):239-43
15272920
Mod Pathol. 2004 Nov;17(11):1359-63
15195111
Int J Oncol. 2004 Dec;25(6):1729-35
15547711
Cancer Res. 2005 May 15;65(10):4238-45
15899815
N Engl J Med. 2005 Jun 9;352(23):2406-12
15944425
Endocr Relat Cancer. 2005 Jun;12(2):245-62
15947100
Virchows Arch. 2005 Jun;446(6):589-95
15902486
Clin Endocrinol (Oxf). 2005 Oct;63(4):461-6
16181240
Clin Endocrinol (Oxf). 2005 Nov;63(5):588-93
16268813
J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9
16174717
JAMA. 2006 May 10;295(18):2164-7
16684987
Endocr Relat Cancer. 2006 Jun;13(2):455-64
16728573
Hum Pathol. 2006 Jul;37(7):781-6
16784975
Cancer Res. 2006 Jul 1;66(13):6521-9
16818623
Clin Endocrinol (Oxf). 2006 Sep;65(3):364-8
16918957
J Clin Endocrinol Metab. 2006 Sep;91(9):3667-70
16772349
Cancer. 2006 Oct 15;107(8):1831-8
16983703
Ann Surg. 2006 Nov;244(5):799-804
17060774